12家中小市值上市公司彰显高成长力 北上协《股东来了》系列活动成功举办

Core Viewpoint - The resilience of small and medium-sized listed companies in China continues to stand out, with effective investor relations management becoming essential for overcoming development bottlenecks and solidifying market value foundations [1][14] Group 1: Activities and Engagement - The Beijing Stock Exchange Association (北上协) has organized the "Shareholders Are Coming" series for two consecutive years, focusing on small and medium-sized listed companies with a market value below 10 billion yuan [2][14] - Over 800 participants, including institutional investors, analysts, and media representatives, engaged in face-to-face communication with 12 small and medium-sized listed companies [1][2] - The activities utilized a "reverse roadshow" approach, allowing investors to visit production facilities and R&D labs, providing a hands-on understanding of company operations [1][13] Group 2: Industry Focus Areas - The series highlighted three key sectors: biomedicine, smart transportation, and digital technology, showcasing the industrial characteristics of companies in Beijing [2] - In biomedicine, companies like Tianzhihang and Nuocheng Jianhua demonstrated innovative products and advancements in healthcare technology [3][4] - Smart transportation was represented by companies like Jiexun Feihong, which showcased their achievements in digital traffic solutions and defense technology [7] - Digital technology was emphasized through companies like Yubang Electric and Zhongke Jincai, focusing on digital infrastructure and AI-driven services [10][11] Group 3: Company Highlights - Tianzhihang's surgical robot is the first globally to cover major orthopedic surgeries, achieving international advanced levels in precision and efficiency [3] - Nuocheng Jianhua's innovative therapies have gained regulatory approval, positioning the company as a leader in hematological and solid tumor treatments [4] - Sanyuan Gene's new smart manufacturing facility incorporates AI technology, marking a significant advancement in gene engineering drug development [5] - Ganjin Pharmaceutical's insulin products dominate the market, reflecting strong competitive positioning [6] - Aibono's medical technology products fill domestic gaps and challenge international monopolies in the vision care sector [6] Group 4: Investor Relations and Market Development - The activities serve as a critical platform for small and medium-sized companies to showcase their value and engage directly with investors, addressing the challenges of information asymmetry [14][15] - The initiative aligns with national policies aimed at enhancing investor protection and promoting long-term capital market development [15] - The ongoing series of activities is set to continue, fostering deeper investor understanding of company strengths and industry prospects [15]